DIACEUTICS PLC

Report Publication Announcement • Sep 11, 2025

National Storage Mechanism | Additional information

RNS Number : 8295Y

Diaceutics PLC

11 September 2025

Diaceutics - Notice of Results & Presentations

New York, Belfast and London, 11 September 2025 - Diaceutics PLC ( AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will announce its un audited results for the half year ended 30 June 2025 on Tuesday, 23 September 2025.

Analyst & Investor Presentation:

A webinar presentation for analysts and investors will be held at 1430 BST (0930 EDT) on Tuesday, 23 September 2025 . Those wishing to attend can register their interest using the following link:

https://us06web.zoom.us/webinar/register/WN_lcoB0C3eSc20_DCSsisB5A

Enquiries:  

Diaceutics PLC
Ryan Keeling, Chief Executive Officer   Nick Roberts, Chief Financial Officer	Tel: +44 (0)28 9040 6500 [email protected]
Canaccord Genuity Limited (Nomad & Broker)	Tel: +44 (0)20 7523 8000
Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORURSURVNUKAAR